Dallas-based BioLum Sciences has been honored as one of 14 companies named the most-innovative startups of 2017 by PM360 magazine.
The publication is a leading magazine for marketing decision makers in the pharmaceutical, biotech, and medical device industries.
The company was chosen as part of PM360’s sixth annual “Innovations Issue,” which capsulizes the year’s most innovative companies, startups, divisions, products, services, and strategies in the health care and life sciences industries.
The issue is published annually in December.
BioLum Sciences was co-founded in 2015 by Southern Methodist University graduates — Chief Technology Officer Miguel Quimbar, CEO Edward Allegra, and Jack Reynolds, chief operating officer and chief financial officer.
Its product, BioSense AMD, will offer asthma patients a way to better assess the presence of and the severity of their symptoms — allowing them to better understand and improve their health, leading to better adherence to treatment, and improved treatment outcomes.
PM360 noted that BioLum’s BioSense AMD will enable rapid, inexpensive, and quantitative determination of hydrogen peroxide in exhaled breath, providing a valuable solution to measure airway inflammation that is attractive to a customer base ranging from patients, biomedical research entities, to specialist doctors, and primary care clinicians.
The magazine said that BioSense AMD has two key innovations:
- The composition of an optimized chemical system where the reaction can be made sensitive to a wide range of analytes through the use of a carefully designed system.
- Methods to image, detect, and quantify the chemical emission through the use of low-cost photon detection instrumentation, and the use of the computational capacity that is an integral component of modern smartphones.
BIOLUM SCIENCES PLANS FOR CLINICAL TRIALS IN 2018
The results of BioLum Sciences’ four research studies have been positive, and the company is preparing for a clinical trial in 2018 to further validate BioSence AMD, PM360 noted.
BioLum announced in September that it had received another round of funding from Intelis Capital, although the amount of the investment was undisclosed.
Proceeds from the investment will be used for product development, commercialization, and next year’s clinical trials, the company said.
Get on the list.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
And, you’ll be the first to get the digital edition of our new Dallas Innovates magazine:
The annual edition publishes in January